WWOX Polymorphisms as Predictors of the Biochemical Recurrence of Localized Prostate Cancer after Radical Prostatectomy

Int J Med Sci. 2023 May 21;20(7):969-975. doi: 10.7150/ijms.84364. eCollection 2023.

Abstract

The downregulation of WW domain-containing oxidoreductase (WWOX), a tumor suppressor gene, is associated with the tumorigenesis and poor prognosis of various cancers. In this study, we investigated the associations between the polymorphisms of WWOX, clinicopathologic features of prostate cancer (PCa), and risk of postoperative biochemical recurrence (BCR). We evaluated the effects of five single-nucleotide polymorphisms (SNPs) of WWOX on the clinicopathologic features of 578 patients with PCa. The risk of postoperative BCR was 2.053-fold higher in patients carrying at least one "A" allele in WWOX rs12918952 than in those with homozygous G/G. Furthermore, patients with at least one polymorphic "T" allele in WWOX rs11545028 had an elevated (1.504-fold) risk of PCa with seminal vesicle invasion. In patients with postoperative BCR, the risks of an advanced Gleason grade and clinical metastasis were 3.317- and 5.259-fold higher in patients carrying at least one "G" allele in WWOX rs3764340 than in other patients. Our findings indicate the WWOX SNPs are significantly associated with highly aggressive pathologic features of PCa and an elevated risk of post-RP biochemical recurrence.

Keywords: WWOX; biochemical recurrence; polymorphism; prostate cancer.

MeSH terms

  • Humans
  • Male
  • Neoplasm Recurrence, Local / pathology
  • Prostate / pathology
  • Prostate-Specific Antigen
  • Prostatectomy
  • Prostatic Neoplasms* / genetics
  • Prostatic Neoplasms* / pathology
  • Prostatic Neoplasms* / surgery
  • Seminal Vesicles* / pathology
  • Tumor Suppressor Proteins / genetics
  • WW Domain-Containing Oxidoreductase / genetics

Substances

  • WW Domain-Containing Oxidoreductase
  • Prostate-Specific Antigen
  • WWOX protein, human
  • Tumor Suppressor Proteins